Rezolute, Inc. 8-K

What Happened

• Rezolute, Inc. (RZLT) issued a press release on May 1, 2026 to announce oral presentation results from its Phase 3 sunRIZE clinical study. The disclosure was reported under Item 7.01 (Regulation FD Disclosure) on Form 8‑K filed May 4, 2026.
• The filing notes the material in the Current Report and Exhibit 99.1 (the press release/poster) is not “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other SEC filings.
• The press release/poster contains forward‑looking statements and includes the company’s caution that actual results may differ and that Rezolute has no obligation to update those statements except as required by law.

Key Details

• Press release date: May 1, 2026; 8‑K filed: May 4, 2026 (Accession No. 0001104659-26-054943).
• Disclosure type: Item 7.01 — Regulation FD Disclosure (oral presentation results from Phase 3 sunRIZE).
• Exhibit included: 99.1 (Press Release dated May 1, 2026). The filing also includes the interactive cover page XBRL file (Exhibit 104).
• The company emphasizes standard forward‑looking statement language and refers investors to its SEC filings (Form 10-K and 10-Q) for risk factors.

Why It Matters

• Publication of Phase 3 study results is a material development for a clinical‑stage company; investors should review the press release/poster for details on efficacy, safety, and next steps.
• The Form 8‑K clarifies the press release is Regulation FD disclosure and contains forward‑looking statements, limiting Section 18 liability and indicating the company is not automatically updating SEC filings with this material.
• Retail investors should read Exhibit 99.1 and Rezolute’s recent SEC filings (including risk factors) to understand the full context before drawing conclusions or making investment decisions.